RANI

RANI THERAPEUTICS HLDGS INC

RANI·753018100·US·Common Stock·Healthcare - Biotechnology-Activist

RANI (RANI THERAPEUTICS HLDGS INC) is held by 39 institutional investors as of Q1 2026. Largest holders: RA CAPITAL MANAGEMENT, L.P. ($6.2M), VANGUARD CAPITAL MANAGEMENT LLC ($3.4M), GEODE CAPITAL MANAGEMENT, LLC ($664,060). Net institutional sentiment: Mixed.

39
Holders
(2 Elite)
$12.7M
Total Value
62% (34)
Consensus
21 buying - 13 selling
13F: Insider & Congress:
RANI

Smart Money Verdict

View all
Held by 39 funds
2 elite

Who's Trading

ActivistVAVanguard Capital Management4.5%Jul 31, 2026
InsiderIAIMRAN MIR ABuy $25KJul 21, 2026
InsiderITImran TalatBuy $25KJul 17, 2026
ActivistSBSamsara BioCapital, L.P.5.0%May 28, 2026
ActivistSYSymBiosis Capital Partners, LLC4.4%May 15, 2026
ActivistVAVanguard Capital Management5.1%Apr 30, 2026
InsiderJAJavadi AlirezaSell $301.08Mar 27, 2026
ActivistThe Vanguard GroupThe Vanguard Group0.0%Mar 27, 2026
ActivistAIAWM Investment Company, Inc.9.9%Feb 13, 2026
InsiderIAIMRAN MIR ABuy $1.3MOct 23, 2025

Top Holders

Fund
Action
Shares
Value
Weight
Est. P&L
Conviction
Unchanged
8.5M$6.2M0.1%-41.33%
0
New
4.6M$3.4M0.0%-42.61%
37
Increased
903,298(+4.9%)$664,0600.0%-71.53%
18
Increased
556,889(+5.5%)$409,2020.0%-38.36%
17
New
455,050$334,4620.0%-42.61%
33
Increased
405,669(+148.4%)$298,0860.0%-42.10%
38
Decreased
373,142(-3.6%)$274,1850.0%-49.91%
0
Increased
227,223(+50.0%)$167,0090.0%-43.35%
21
Increased
188,222(+231.3%)$138,3060.0%-42.23%
24
Unchanged
170,471$125,2620.0%-74.53%
0
New
165,599$121,6820.0%-42.61%
34
New
153,331$112,6680.0%-42.61%
30
Unchanged
78,000$57,3140.0%-41.33%
0
Increased
76,500(+10.6%)$56,2120.0%-41.46%
23
Unchanged
58,000$42,6180.0%-69.34%
0
Decreased
47,508(-68.0%)$34,9090.0%-41.33%
0
New
31,751$23,3370.0%-42.61%
29
Decreased
24,370(-15.0%)$17,9070.0%-47.22%
0
New
23,336$17,1470.0%-42.61%
25
Decreased
22,221(-25.6%)$16,3280.0%-41.33%
0

Showing 1-20 of 42

1 / 3
RANIRANIRANI THERAPEUTICS HLDGS INC

Other Healthcare stocks held by institutions

Data sourced from four public-disclosure sources: SEC 13F, Form 4, 13D/13G, and House/Senate STOCK Act disclosures. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used